The European Commission is predicting that by 2020 Europe will need an additional one million clinical professionals to care for its ageing population. With many of our cancer systems already working at full capacity, this Editorial calls on the cancer community to get engaged in discussions about the changes in working practices, training and workforce mix that will be needed to safeguard the quality and safety of the care we provide.
Patients look for the best treatment centres, says this leading voice in European urology. So theyÂ’ll go where the specialists involved in their care work together, not where they are constantly battling over who is Â‘in chargeÂ’.
Recent years have seen a revival of interest in the unique metabolism of cancer cells. This time the focus is on the potential it offers as a target, rather than any possible causal role Â– but that link with obesity still needs explaining.
Patient advocates believe their input into guiding the research process is key to ensuring the right questions are investigated in the right way. Where itÂ’s been successfully tried, both sides agree there is no going back.
Getting cancer as a teenager or young adult can severely disrupt an important period of emotional, physical and social transition. Tailoring services to fit the particular needs of this age group can make a huge difference.
A shared sense of the value of helping people with incurable cancers achieve lives worth living has driven doctors to collaborate across borders for decades. An oncologist shares his experiences from the Cold War to the present day.
If Tomasetti and Vogelstein had not used the words Â“bad luckÂ” in their paper on how Â‘variation in cancer risk among tissues can be explained by the number of stem cell divisionsÂ’, the media might not have covered the story the way they did. In this interview with The Cancer Letter, Bertram Kramer, head of Cancer Prevention at the US National Cancer Institute, tries to clear up some of the confusion.
Over the past decade, genetic testing for rare inherited mutations, such as BRCA1 and BRCA2 mutations, has been successfully incorporated into clinical practice. Next-generation sequencing of cancer-susceptibility genes and entire tumour genomes has transformed cancer care and prevention. The discoveries of new cancer syndromes have raised exciting opportunities and potential liabilities for cancer-care providers seeking to incorporate genomic approaches into preventive oncology practice.
Selected reports edited by Janet Fricker